Navigation Links
Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis
Date:2/2/2011

RESEARCH TRIANGLE PARK, N.C., Feb. 2, 2011 The day when a surgeon can pull a new human vein off the shelf for use in life-saving vascular surgeries is now one step closer to reality. New research published in the current issue of the journal, Science Translational Medicine, demonstrates the efficacy of tissue-engineered vascular grafts (TEVGs) that are immediately-available at the time of surgery and have decreased potential for infection, obstruction or clotting. The bioengineering method of producing veins reported in the newly-published research shows promise in both large and small diameter applications, such as for Coronary Artery Bypass Graft (CABG) surgery and for vascular access in hemodialysis.

Coronary Artery Bypass Graft (CABG) Surgery

The American Heart Association Update on Heart Disease Statistics reports that in 2007, in the U.S., just over 400,000 coronary bypass procedures were performed. Patients requiring bypass surgery may not have suitable veins or arteries available and are not candidates for synthetic grafts because of the size needed for grafting.

This new type of bioengineered vein allows them to be easily stored in hospitals so they are readily available to surgeons at the time of need, said Alan P. Kypson, M.D., Associate Professor of Cardiothoracic Surgery, Brody School of Medicine, at East Carolina University, also an author of the paper. Currently, grafting using the patients own veins remains the gold standard. But, harvesting a vein from the patients leg can lead to complications, and for patients who dont have suitable veins, the bioengineered veins could serve as an important new way to provide a coronary bypass.

Kidney Hemodialysis

According to statistics published by the National Kidney Foundation, 320,000 patients are on chronic hemodialysis. Each year, 110,000 new patients develop renal failure requiring dialysis, and the number is growing by three percent per year. More than half of dialysis patients lack the healthy veins necessary and must undergo an arteriovenous graft (AV graft) placement in order to have bloodstream access for hemodialysis.

Most AV grafts that are placed for hemodialysis access are comprised of a synthetic material, which suffers from significant drawbacks including a high rate of infection, or a propensity for occlusion due to thrombosis and intimal hyperplasia, said Jeffrey H. Lawson, M.D., Ph.D., Associate Professor of Surgery at Duke University School of Medicine and an author of the research. Due to high complication rates, each AV dialysis graft requires an average of 2.8 interventions over its lifetime just to keep it functioning. Hence, there is a huge clinical need for a functionally superior, off-the-shelf, AV graft that suffers from fewer complications than current materials.

The research was conducted by scientists from Duke University, East Carolina University, Yale University, and Humacyte, and was funded by Humacyte, a leader in regenerative medicine. Overseeing the research and senior author of the article was Laura Niklason, M.D., Ph.D., founder of Humacyte, and Professor of Anesthesiology and of Biomedical Engineering at Yale University. Niklason is a recognized authority in regenerative medicine for arterial engineering and was leader of the team that recently created a functioning rat lung in a laboratory.

Not only are bioengineered veins available at the time of patient need, but the ability to generate a significant number of grafts from a cell bank will allow for a reduction in the final production costs, as compared to other regenerative medicine strategies, added lead author Shannon L. M. Dahl, Senior Director of Scientific Operations and Co-Founder of Humacyte, Inc. While there is still considerable research to be done before a product is available for widespread use, we are highly encouraged by the results outlined in this paper and eager to move forward with additional study, Dahl said.

About The Research

In this research, bioengineered veins were generated in a bioreactor, decellularized, and stored up to 12 months in refrigerated conditions. Then bioengineered veins (3-6mm in diameter) demonstrated excellent blood flow and resistance to occlusion in large animal models for up to one year.


'/>"/>

Contact: Julie Lux
julie@westmillconsulting.com
816-807-9972
West Mill Consulting
Source:Eurekalert  

Related biology technology :

1. Creating Functional Hepatic Tissue in a Bioengineered Human Liver
2. Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk
3. Microbes, Inc. Extends Warrant Tender Offer
4. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
5. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
6. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
7. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
8. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
9. Minnesota Chiropractic Association Offers Backpack Safety Checklist
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):